A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer

NCT02096354 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Neoplasms

Interventions

DRUG: RRx-001
DRUG: Regorafenib
DRUG: Irinotecan

Sponsor

EpicentRx, Inc.